Regulation 30 Approval of Composite scheme of Arrangement
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 25 Jun 2026, 07:10 PM IST · BSE ID: e34ee877-7b94-4cbd-88e1-294733146f3a
View Original BSE Filing (PDF)
💡
In Simple Terms
Astral Ltd's board approved a plan to separate its chemicals business into a new company and merge another firm into itself.
🤖 AI Summary
- Astral Ltd's Board approved a Composite Scheme of Arrangement, demerging its Chemicals Business Undertaking.
- The demerged Chemicals Business Undertaking reported a turnover of ₹ 12,663 million for the year ended March 31, 2026.
- This demerged undertaking contributed 21% to Astral Ltd's total turnover for the year ended March 31, 2026.
- The scheme also involves the amalgamation of Al-Aziz Plastics Private Limited into Astral Ltd.
- Astral Chemie Limited will issue 1 equity share of ₹1/- face value for every 1 equity share of ₹1/- held in Astral Ltd.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Turnover of Demerged Undertaking (FY26)
₹ 12,663 million
Demerged Undertaking Turnover % of Total (FY26)
21%
🏢 How This Affects the Company
Astral Ltd will demerge its Chemicals Business Undertaking, which accounted for 21% of its total turnover for the year ended March 31, 2026, into a separate entity. This reorganisation aims to streamline business segments.
The demerger of the Chemicals Business Undertaking, with a turnover of ₹ 12,663 million in FY26, will lead to a re-allocation of assets and liabilities to Astral Chemie Limited. Post-demerger, Astral Ltd's standalone financial reporting will exclude the demerged chemicals business.
The Chemicals Business Undertaking will transfer its operations, activities, and properties to Astral Chemie Limited, which will operate on a going concern basis. This restructuring separates the chemicals segment from Astral Ltd's core business.
The implementation of the scheme is subject to various regulatory approvals including from NCLT, SEBI, and Stock Exchanges, introducing execution risk. Failure to obtain approvals would prevent the scheme's effectiveness.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action following this board approval.
👤
Who Is Affected
Existing shareholders of Astral Limited will receive 1 equity share of Astral Chemie Limited for every 1 equity share they hold in Astral Limited, effectively mirroring their existing holding in the demerged entity.
🔍
Management Signal
The decision reveals management's intent to restructure its business operations by separating the Chemicals Business Undertaking and integrating Al-Aziz Plastics Private Limited.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
National Company Law Tribunal (NCLT) approval status for the Composite Scheme.
Securities and Exchange Board of India (SEBI) approval status for the scheme.
Announcement of the Record Date for the share allotment in Astral Chemie Limited.
MEDIUM RISK
The scheme's completion is dependent on obtaining various statutory and regulatory approvals, which introduces execution uncertainty.
💡 Investor Takeaway
Astral Ltd's board approved a Composite Scheme of Arrangement, demerging its Chemicals Business Undertaking (FY26 turnover ₹ 12,663 million) into Astral Chemie Limited and amalgamating Al-Aziz Plastics Private Limited into Astral Ltd. The scheme is subject to multiple regulatory approvals.
⚖️ Strengths & Concerns
✅ Positives
- Demerged Chemicals Business Undertaking generated ₹ 12,663 million in turnover for FY26, establishing a significant operational base for the Resulting Company.
- The scheme ensures a clear share exchange ratio: 1 equity share of Astral Chemie Limited for every 1 equity share held in Astral Limited.
⚠️ Concerns
- The entire scheme is contingent on receiving multiple statutory and regulatory approvals from authorities including NCLT and SEBI.
- There is no immediate financial consideration being discharged under the scheme, with only a share exchange ratio for the demerger.
❓ Frequently Asked Questions
What is the key decision made by Astral Ltd's Board on June 25, 2026?
Astral Ltd's Board approved a Composite Scheme of Arrangement for the demerger of its Chemicals Business Undertaking into Astral Chemie Limited and the amalgamation of Al-Aziz Plastics Private Limited into Astral Ltd.
What was the turnover of the demerged Chemicals Business Undertaking for the year ended March 31, 2026?
The turnover of the demerged Chemicals Business Undertaking for the year ended March 31, 2026, stood at ₹ 12,663 million.
What percentage of Astral Ltd's total turnover did the demerged Chemicals Business Undertaking represent?
The demerged Chemicals Business Undertaking represented 21% of Astral Ltd's total turnover for the year ended March 31, 2026.
What is the share exchange ratio for the demerger of the Chemicals Business Undertaking?
Astral Chemie Limited will issue 1 (One) Equity Share of a face value of ₹1/- each for every 1 (One) Equity Share of a face value of ₹1/- each held in Astral Limited.
Are there any pending approvals for this Composite Scheme of Arrangement?
Yes, the scheme is subject to requisite approvals from the National Company Law Tribunal, SEBI, Stock Exchanges, and other statutory and regulatory authorities, as well as respective shareholders and creditors.
Questions based on this BSE filing only. For information purposes.